Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
| ▸ | CA2 | P00918 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | CNR2 | P34972 | 2/20 | 0.55 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.55 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4928502 | 0.85 | HTT (0.73) | HTTSMN1; SMN2NPC1LMNACA1 | |
| SCHEMBL11796135 | 0.84 | AOC2 (0.66) | HTTMEN1KMT2AAOC2 | |
| SCHEMBL10684986 | 0.83 | HTT (0.76) | HTTSMN1; SMN2NPC1LMNATDP1 | |
| SCHEMBL3369060 | 0.83 | HTT (0.76) | HTTSMN1; SMN2NPC1LMNATDP1 | |
| SCHEMBL13903016 | 0.82 | ALDH1A1 (0.67) | HTTSMN1; SMN2CA1CA2ALDH1A1 | |
| SCHEMBL3369054 | 0.81 | HTT (0.73) | HTTSMN1; SMN2NPC1LMNATDP1 | |
| SCHEMBL29907960 | 0.81 | MAPK8 (0.54) | HTTCA1CA2MEN1KMT2A | |
| SCHEMBL7905681 | 0.80 | HTT (0.71) | HTTSMN1; SMN2NPC1LMNATDP1 | |
| SCHEMBL2450845 | 0.80 | HTT (0.71) | HTTSMN1; SMN2NPC1LMNACA1 | |
| SCHEMBL30034264 | 0.80 | SMN1; SMN2 (0.88) | HTTSMN1; SMN2LMNACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041672-A1 | Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Pharmaceutical Compositions, and Uses Thereof | UNIV EMORY (US) | 2026-02-12 | — | — | US | disclosed |
| US-12465595-B2 | Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, pharmaceutical compositions, and uses thereof | EMORY UNIVERSITY (US) | 2025-11-11 | — | — | US | disclosed |
| EP-3541802-B1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2025-01-01 | — | — | EP | disclosed |
| US-11912687-B2 | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof | Board of Trustees of the Southern Illinois University (US) | 2024-02-27 | — | — | US | disclosed |
| CN-114989131-B | N' - (2- (benzo [1,3] dioxolan-5-yl) acyl) aryl hydrazide compound as well as synthesis and application thereof | 云南大学 | 2023-10-24 | — | — | CN | disclosed |
| US-20230293498-A1 | Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Pharmaceutical Compositions, and Uses Thereof | EMORY UNIVERSITY | 2023-09-21 | — | — | US | disclosed |
| EP-3634406-B1 | 3,4,5-TRISUBSTITUTED-1,2,4-TRIAZOLES AND 3,4,5-TRISUBSTITUTED-3-THIO-1,2,4-TRIAZOLES AND USES THEREOF | BOARD OF TRUSTEES OF THE SOUTHERN ILLINOIS UNIV ON BEHALF OF SOUTHERN ILLINOIS UNIV EDWARDSVILLE (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-3634406-B1 | 3,4,5-TRISUBSTITUTED-1,2,4-TRIAZOLES AND 3,4,5-TRISUBSTITUTED-3-THIO-1,2,4-TRIAZOLES AND USES THEREOF | BOARD OF TRUSTEES OF THE SOUTHERN ILLINOIS UNIV ON BEHALF OF SOUTHERN ILLINOIS UNIV EDWARDSVILLE (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-4188365-A2 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) MODULATORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Emory University (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-114989131-A | N' - (2- (benzo [1,3] dioxolane-5-yl) acyl) aroyl hydrazide compound and synthesis and application thereof | 云南大学 | 2022-09-02 | — | — | CN | disclosed |
| US-5952359-A | NEMATICIDES, INSECTICIDES AND MITICIDES; 1,1-DIFLUORO-3-(THIAZOLYL OR ISOTHIAZOYL-THIO (OR SULFINYL OR SULFONYL)-PROP-1-ENE DERIVATIVES | ZENECA LIMITED (GB) | 1999-09-14 | — | — | US | disclosed |
| US-5912243-A | NOVEL COMPOUNDS FOR CONTROLLING NEMATODES, INSECT OR ACARID PESTS | ZENECA LIMITED (GB) | 1999-06-15 | — | — | US | disclosed |
| US-5705516-A | NEMATOCIDES, INSECTICIDES, ACARICIDES | ZENECA LIMITED (GB) | 1998-01-06 | — | — | US | disclosed |
| CN-1143958-A | (4,4-difluorobut-3-enylthio-)-substituted heterocyclic or carbocyclic ring compounds | ZENECA LTD (GB) | 1997-02-26 | — | — | CN | disclosed |
| EP-0749433-A1 | (4,4-DIFLUOROBUT-3-ENYLTHIO)-SUBSTITUTED HETEROCYCLIC OR CARBOCYCLIC RING COMPOUNDS HAVING PESTICIDAL ACTIVITY | ZENECA LIMITED (GB) | 1996-12-27 | — | — | EP | disclosed |
| WO-1995024403-A1 | (4,4-DIFLUOROBUT-3-ENYLTHIO)-SUBSTITUTED HETEROCYCLIC OR CARBOCYCLIC RING COMPOUNDS HAVING PESTICIDAL ACTIVITY | ZENECA LIMITED (GB) | 1995-09-14 | — | — | WO | disclosed |
| EP-0348139-B1 | Photograhic materials and process | EASTMAN KODAK CO (US) | 1995-07-19 | — | — | EP | disclosed |
| US-4962018-A | TIMED RELEASE DEVELOPMENT INHIBITOR | EASTMAN KODAK COMPANY (US) | 1990-10-09 | — | — | US | disclosed |
| EP-0348139-A2 | Photograhic materials and process | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1989-12-27 | — | — | EP | disclosed |
| US-4150139-A | MUSCLE RELAXANTS, ANALGESICS, ANTIINFLAMMATORY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1979-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041672-A1 | Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Pharmaceutical Compositions, and Uses Thereof | CFTR, SCNN1B, CLCN2 | HTT 1765/4885SMN1; SMN2 4234/4885NPC1 423/4885 |
| US-12465595-B2 | Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, pharmaceutical compositions, and uses thereof | CFTR, CLCN2, SLC26A4 | HTT 2954/4885SMN1; SMN2 4495/4885NPC1 228/4885 |
| US-20230293498-A1 | Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Pharmaceutical Compositions, and Uses Thereof | CFTR, CLCN2, SLC26A4 | HTT 2954/4885SMN1; SMN2 4495/4885NPC1 228/4885 |
| US-11912687-B2 | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof | SSTR4, SSTR5, SSTR3 | HTT 4043/4885SMN1; SMN2 4126/4885NPC1 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.